A biomarker assay to risk-stratify patients with symptoms of respiratory tract infection.

Shahid Husain,Andrew T Sage,Lorenzo Del Sorbo,Marcelo Cypel,Tereza Martinu,Stephen C Juvet,Andrea Mariscal,Julie Wright,Bonnie T Chao,Alaa A Shamandy,S Hossein Mousavi,Jin Ma,Bo Wang,Jerome Valero,Mingyao Liu,Megan Landes, Sharaniyaa Balachandran, Kimberley Hudson,Michelle Ngai,Marialessia Capuano,Maria Gelardi,Enrico Lupia, Daniel R Marinowic,Frederico O Friedrich, Carine R R Schmitz, Leticya S M Dos Santos,Florencia M Barbe-Tuana,Marcus H Jones,Kevin C Kain,Tony Mazzulli,Sam Sabbah,Shaf Keshavjee

The European respiratory journal（2022）

引用 3|浏览17

暂无评分

摘要

The rapid diagnostic biomarker panel accurately identified the need for inpatient care in patients presenting with respiratory symptoms, including COVID-19. The RALI-Dx test is broadly and easily applicable across many jurisdictions, and represents an important diagnostic adjunct to advance ED decision-making protocols.

查看译文

关键词

biomarker,infection,risk-stratify

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要